Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies

Journal of Neurochemistry

Volumn 139, Issue , 2016, Pages 240-255

  Villar Piqué, Anna ^a   Lopes da Fonseca, Tomás ^a,b   Outeiro, Tiago Fleming ^a,b,c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

alpha synuclein; amyloid fibrils; oligomers; synapses; synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; OLIGOMER; PROTEIN AGGREGATE;

CELL FUNCTION; CELL MEMBRANE; CELL STRUCTURE; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; GENE MUTATION; HUMAN; INTRACELLULAR TRANSPORT; LEWY BODY; MEDICAL RESEARCH; MITOCHONDRION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN METABOLISM; PROTEIN MISFOLDING; PROTEIN PROCESSING; PROTEIN STRUCTURE; PURE AUTONOMIC FAILURE; REVIEW; SHY DRAGER SYNDROME; SYNUCLEINOPATHY; TOXICITY; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN FOLDING;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATES; PROTEIN FOLDING;

EID: 84941584642     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13249     Document Type: Review

References (207)

1. Abeliovich A., Schmitz Y., Fariñas I. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252.
2. Al-Chalabi A., Dürr A., Wood N. W. et al. (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 4, e7114.
3. Apetri M. M., Maiti N. C., Zagorski M. G., Carey P. R. and Anderson V. E. (2006) Secondary structure of alpha-synuclein oligomers: characterization by raman and atomic force microscopy. J. Mol. Biol. 355, 63–71.
4. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M. et al. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28, 811–813.
5. Arai K., Kato N., Kashiwado K. and Hattori T. (2000) Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci. Lett. 296, 171–173.
6. Bartels T., Choi J. G. and Selkoe D. J. (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107–110.
7. Basso E., Antas P., Marijanovic Z., Gonçalves S., Tenreiro S. and Outeiro T. F. (2013) PLK2 modulates α-synuclein aggregation in yeast and mammalian cells. Mol. Neurobiol. 48, 854–862.
8. Bellucci A., Navarria L., Zaltieri M., Falarti E., Bodei S., Sigala S., Battistin L., Spillantini M., Missale C. and Spano P. (2011) Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J. Neurochem. 116, 588–605.
9. Bendor J. T., Logan T. P. and Edwards R. H. (2013) The function of α-synuclein. Neuron 79, 1044–1066.
10. Bertoncini C. W., Fernandez C. O., Griesinger C., Jovin T. M. and Zweckstetter M. (2005a) Familial mutants of α-synuclein with increased neurotoxicity have a destabilized conformation. J. Biol. Chem. 280, 30649–30652.
11. Bertoncini C. W., Jung Y.-S., Fernandez C. O., Hoyer W., Griesinger C., Jovin T. M. and Zweckstetter M. (2005b) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl Acad. Sci. USA 102, 1430–1435.
12. Binolfi A., Theillet F.-X. and Selenko P. (2012) Bacterial in-cell NMR of human α-synuclein: a disordered monomer by nature? Biochem. Soc. Trans. 40, 950–954.
13. Bodner R. A., Outeiro T. F., Altmann S., Maxwell M. M., Cho S. H., Hyman B. T., McLean P. J., Young A. B., Housman D. E. and Kazantsev A. G. (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl Acad. Sci. USA 103, 4246–4251.
14. Bousset L., Pieri L., Ruiz-Arlandis G. et al. (2013) Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575.
15. Breydo L., Wu J. W. and Uversky V. N. (2012) Alpha-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 1822, 261–285.
16. Buell A. K., Galvagnion C., Gaspar R., Sparr E., Vendruscolo M., Knowles T. P. J., Linse S. and Dobson C. M. (2014) Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc. Natl Acad. Sci. USA 111, 7671–7676.
17. Burré J., Sharma M., Tsetsenis T., Buchman V., Etherton M. R. and Südhof T. C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667.
18. Burré J., Sharma M. and Sudhof T. C. (2012) Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 32, 15227–15242.
19. Burré J., Sharma M. and Südhof T. C. (2014) α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. 111, E4274–E4283.
20. Burré J., Sharma M. and Südhof T. C. (2015) Definition of a molecular pathway mediating α-synuclein neurotoxicity. J. Neurosci. 35, 5221–5232.
21. Bussell R. and Eliezer D. (2001) Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J. Biol. Chem. 276, 45996–46003.
22. Cabin D. E., Shimazu K., Murphy D. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797–8807.
23. Carulla N., Caddy G. L., Hall D. R., Zurdo J., Gairí M., Feliz M., Giralt E., Robinson C. V. and Dobson C. M. (2005) Molecular recycling within amyloid fibrils. Nature 436, 554–558.
24. Castillo-Carranza D. L., Zhang Y., Guerrero-Muñoz M. J., Kayed R., Rincon-Limas D. E. and Fernandez-Funez P. (2012) Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem. Res. 37, 1707–1717.
25. Celej M. S., Sarroukh R., Goormaghtigh E., Fidelio G. D., Ruysschaert J. and Raussens V. (2012) Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. Biochem. J. 443, 719–726.
26. Chandra S., Fornai F., Kwon H.-B. et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl Acad. Sci. USA 101, 14966–14971.
27. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O. M. and Südhof T. C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123, 383–396.
28. Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167–1169.
29. Chaudhuri K. R., Healy D. G. and Schapira A. H. (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235–245.
30. Chen L., Jin J., Davis J., Zhou Y., Wang Y., Liu J., Lockhart P. J. and Zhang J. (2007) Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem. Biophys. Res. Commun. 356, 548–553.
31. Chen L., Periquet M., Wang X., Negro A., McLean P. J., Hyman B. T. and Feany M. B. (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 119, 3257–3265.
32. Chen L., Xie Z., Turkson S. and Zhuang X. (2015) A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J. Neurosci. 35, 890–905.
33. Chesselet M. F. (2008) In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease? Exp. Neurol. 209, 22–27.
34. Chinta S. J., Mallajosyula J. K., Rane A. and Andersen J. K. (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486, 235–239.
35. Cho M. K., Kim H. Y., Fernandez C. O., Becker S. and Zweckstetter M. (2011) Conserved core of amyloid fibrils of wild type and A30P mutant alpha-synuclein. Protein Sci. 20, 387–395.
36. Choi B.-K., Choi M.-G., Kim J.-Y., Yang Y., Lai Y., Kweon D.-H., Lee N. K. and Shin Y.-K. (2013) Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl Acad. Sci. USA 110, 4087–4092.
37. Chu Y., Dodiya H., Aebischer P., Olanow C. W. and Kordower J. H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398.
38. Chu Y., Morfini G. A., Langhamer L. B., He Y., Brady S. T. and Kordower J. H. (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135, 2058–2073.
39. Chutna O., Gonçalves S., Villar-Piqué A. et al. (2014) The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Hum. Mol. Genet. 23, 6732–6745.
40. Colla E., Coune P., Liu Y., Pletnikova O., Troncoso J. C., Iwatsubo T., Schneider B. L. and Lee M. K. (2012a) Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32, 3306–3320.
41. Colla E., Jensen P. H., Pletnikova O., Troncoso J. C., Glabe C. and Lee M. K. (2012b) Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32, 3301–3305.
42. Comellas G., Lemkau L. R., Nieuwkoop A. J., Kloepper K. D., Ladror D. T., Ebisu R., Woods W. S., Lipton A. S., George J. M. and Rienstra C. M. (2011) Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. J. Mol. Biol. 411, 881–895.
43. Conway K. A., Harper J. D. and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318–1320.
44. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571–576.
45. Cooper A. A., Gitler A. D., Cashikar A. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324–328.
46. Cremades N., Cohen S. I. A., Deas E. et al. (2012) Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048–1059.
47. Crews L., Spencer B., Desplats P., Patrick C., Paulino A., Rockenstein E., Hansen L., Adame A., Galasko D. and Masliah E. (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE 5, e9313.
48. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295.
49. Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P. and Vila M. (2010) Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535–12544.
50. Desplats P., Spencer B., Crews L. et al. (2012) α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of notch. J. Biol. Chem. 287, 31691–31702.
51. Devi L., Raghavendran V., Prabhu B. M., Avadhani N. G. and Anandatheerthavarada H. K. (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089–9100.
52. Diao J., Burré J., Vivona S., Cipriano D. J., Sharma M., Kyoung M., Südhof T. C. and Brunger A. T. (2013) Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2, e00592.
53. Diogenes M. J., Dias R. B., Rombo D. M. et al. (2012) Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32, 11750–11762.
54. Donadio V., Incensi A., Cortelli P., Giannoccaro M. P., Jaber M. A., Baruzzi A. and Liguori R. (2013) Skin sympathetic fiber alpha-synuclein deposits: A potential biomarker for pure autonomic failure. Neurology 80, 725–732.
55. Donaghy P. and McKeith I. (2014) The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res. Ther. 6, 46.
56. Duke D. C., Moran L. B., Kalaitzakis M. E., Deprez M., Dexter D. T., Pearce R. K. B. and Graeber M. B. (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7, 139–148.
57. Edwards T. L., Scott W. K., Almonte C. et al. (2010) Genome-Wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for parkinson disease. Ann. Hum. Genet. 74, 97–109.
58. Ehrnhoefer D. E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A. and Wanker E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558–566.
59. Emmanouilidou E., Stefanis L. and Vekrellis K. (2010) Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 31, 953–968.
60. Eschbach J. and Danzer K. M. (2014) α-Synuclein in parkinson's disease: pathogenic function and translation into animal models. Neurodegener. Dis. 14, 1–17.
61. Fagerqvist T., Näsström T., Ihse E. et al. (2013) Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo. Amyloid 20, 233–244.
62. Fares M. B., Ait-Bouziad N., Dikiy I. et al. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 23, 4491–4509.
63. Fauvet B., Mbefo M. K., Fares M. B. et al. (2012) α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 15345–15364.
64. Fujita Y., Ohama E., Takatama M., Al-Sarraj S. and Okamoto K. (2006) Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol. 112, 261–265.
65. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164.
66. Furukawa Y., Vigouroux S., Wong H., Guttman M., Rajput A. H., Ang L., Briand M., Kish S. J. and Briand Y. (2002) Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann. Neurol. 51, 779–782.
67. Garland E. M., Hooper W. B. and Robertson D. (2013) Pure autonomic failure. Handb. Clin. Neurol. 117, 243–257.
68. Ga̧ssowska M., Czapski G. A., Pajaķ B., Ciesĺik M., Lenkiewicz A. M. and Adamczyk A. (2014) Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent tau phosphorylation in PC12 cells. PLoS ONE 9, e94259.
69. Gegg M. E., Burke D., Heales S. J. R., Cooper J. M., Hardy J., Wood N. W. and Schapira A. H. V. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455–463.
70. Ghosh D., Sahay S., Ranjan P. et al. (2014) The newly discovered Parkinson's disease associated finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding. Biochemistry 53, 6419–6421.
71. Ghosh D., Singh P. K., Sahay S., Jha N. N., Jacob R. S., Sen S., Kumar A., Riek R. and Maji S. K. (2015) Structure based aggregation studies reveal the presence of helix-rich intermediate during alpha-synuclein aggregation. Sci. Rep. 5, 9228.
72. Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985–989.
73. Gitler A. D., Bevis B. J., Shorter J. et al. (2008) The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis. Proc. Natl Acad. Sci. USA 105, 145–150.
74. Goers J., Manning-Bog A. B., McCormack A. L., Millett I. S., Doniach S., Monte D. A. Di., Uversky V. N. and Fink A. L. (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465–8471.
75. Gonçalves S. and Outeiro T. F. (2013) Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol. Neurobiol. 47, 1081–1092.
76. Gosavi N., Lee H. J., Lee J. S., Patel S. and Lee S. J. (2002) Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277, 48984–48992.
77. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. and Giasson B. I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800–7807.
78. Greten-Harrison B., Polydoro M., Morimoto-Tomita M. et al. (2010) αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl Acad. Sci. USA 107, 19573–19578.
79. Haberman A., Williamson W. R., Epstein D., Wang D., Rina S., Meinertzhagen I. A. and Hiesinger P. R. (2012) The synaptic vesicle SNARE neuronal synaptobrevin promotes endolysosomal degradation and prevents neurodegeneration. J. Cell Biol. 196, 261–276.
80. Hoozemans J. J. M., van Haastert E. S., Eikelenboom P., de Vos R. A. I., Rozemuller J. M. and Scheper W. (2007) Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354, 707–711.
81. Hoozemans J. J. M., van Haastert E. S., Nijholt D. A. T., Rozemuller A. J. M. and Scheper W. (2012) Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. Neurodegener. Dis. 10, 212–215.
82. Huang Z., Xu Z., Wu Y. and Zhou Y. (2011) Determining nuclear localization of alpha-synuclein in mouse brains. Neuroscience 199, 318–332.
83. Invernizzi G., Papaleo E., Sabate R. and Ventura S. (2012) Protein aggregation: mechanisms and functional consequences. Int. J. Biochem. Cell Biol. 44, 1541–1554.
84. Jankovic J. (2008) Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368–376.
85. Jo E., Fuller N., Rand R. P., St George-Hyslop P. and Fraser P. E. (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J. Mol. Biol. 315, 799–807.
86. Karpinar D. P., Balija M. B. G., Kügler S. et al. (2009) Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28, 3256–3268.
87. Kaufmann H., Nahm K., Purohit D. and Wolfe D. (2004) Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63, 1093–1095.
88. Kaylor J., Bodner N., Edridge S., Yamin G., Hong D. P. and Fink A. L. (2005) Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J. Mol. Biol. 353, 357–372.
89. Kiely A. P., Asi Y. T., Kara E. et al. (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753–769.
90. Kontopoulos E., Parvin J. D. and Feany M. B. (2006) α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012–3023.
91. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106–108.
92. Lai Y., Kim S., Varkey J., Lou X., Song J. K., Diao J., Langen R. and Shin Y. K. (2014) Nonaggregated α-synuclein influences snare-dependent vesicle docking via membrane binding. Biochemistry 53, 3889–3896.
93. Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. and Lansbury P. T. (2002) α-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102.
94. Lázaro D. F., Rodrigues E. F., Langohr R. et al. (2014) Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 10, e1004741.
95. Lee H. J., Khoshaghideh F., Lee S. and Lee S. J. (2006) Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 24, 3153–3162.
96. Lee S. J., Jeon H. and Kandror K. V. (2008) Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol. Exp. (Wars) 68, 509–515.
97. Lee K.-W., Chen W., Junn E. et al. (2011) Enhanced phosphatase activity attenuates α-Synucleinopathy in a mouse model. J. Neurosci. 31, 6963–6971.
98. Lesage S., Anheim M., Letournel F. et al. (2013) G51D alpha-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459–471.
99. Li J., Uversky V. N. and Fink A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-Synuclein. Biochemistry 40, 11604–11613.
100. Li J., Uversky V. N. and Fink A. L. (2002) Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology 23, 553–567.
101. Lin D. J., Hermann K. L. and Schmahmann J. D. (2014) Multiple system atrophy of the cerebellar type: clinical state of the art. Mov. Disord. 29, 294–304.
102. Lindersson E., Beedholm R., Højrup P., Moos T., Gai W., Hendil K. B. and Jensen P. H. (2004) Proteasomal inhibition by α-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924–12934.
103. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Uéda K., Chan P. and Yu S. (2009) alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 454, 187–192.
104. Liu X., Lee Y. J., Liou L. C., Ren Q., Zhang Z., Wang S. and Witt S. N. (2011) Alpha-synuclein functions in the nucleus to protect against hydroxyurea-induced replication stress in yeast. Hum. Mol. Genet. 20, 3401–3414.
105. Loeb V., Yakunin E., Saada A. and Sharon R. (2010) The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 285, 7334–7343.
106. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M.-Y. (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953.
107. Luth E. S., Stavrovskaya I. G., Bartels T., Kristal B. S. and Selkoe D. J. (2014) Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289, 21490–21507.
108. Lv G., Kumar A., Giller K., Orcellet M. L., Riedel D., Fernández C. O., Becker S. and Lange A. (2012) Structural comparison of mouse and human α-synuclein amyloid fibrils by solid-state NMR. J. Mol. Biol. 420, 99–111.
109. Makioka K., Yamazaki T., Fujita Y., Takatama M., Nakazato Y. and Okamoto K. (2010) Involvement of endoplasmic reticulum stress defined by activated unfolded protein response in multiple system atrophy. J. Neurol. Sci. 297, 60–65.
110. Maroteaux L., Campanelli J. T. and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804–2815.
111. Martinez T. N. and Greenamyre J. T. (2012) Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signal. 16, 920–934.
112. Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D. M. A. and Hasegawa M. (2013) Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128–1138.
113. McNaught K. S. P. and Jenner P. (2001) Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297, 191–194.
114. McNaught K. S. P., Belizaire R., Jenner P., Olanow C. W. and Isacson O. (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155–158.
115. Melachroinou K., Xilouri M., Emmanouilidou E., Masgrau R., Papazafiri P., Stefanis L. and Vekrellis K. (2013) Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853–2865.
116. Melki R. (2015) Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J. Parkinsons. Dis. 5, 217–227.
117. Milanesi L., Sheynis T., Xue W.-F., Orlova E. V., Hellewell A. L., Jelinek R., Hewitt E. W., Radford S. E. and Saibil H. R. (2012) Direct three-dimensional visualization of membrane disruption by amyloid fibrils. Proc. Natl Acad. Sci. USA 109, 20455–20460.
118. Morais V. A., Verstreken P., Roethig A. et al. (2009) Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 1, 99–111.
119. Murphy K. E., Gysbers A. M., Abbott S. K., Tayebi N., Kim W. S., Sidransky E., Cooper A., Garner B. and Halliday G. M. (2014) Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137, 834–848.
120. Nakamura K. (2013) α-Synuclein and mitochondria: partners in crime? Neurotherapeutics 10, 391–399.
121. Nakamura K., Nemani V. M., Azarbal F. et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 286, 20710–20726.
122. Nalls M. a., Pankratz N., Lill C. M. et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989–993.
123. Norris K. L., Hao R., Chen L.-F. et al. (2015) Convergence of Parkin, PINK1, and α-synuclein on stress-induced mitochondrial morphological remodeling. J. Biol. Chem. 290, 13862–13874.
124. Olanow C. W., Perl D. P., DeMartino G. N. and McNaught K. S. P. (2004) Lewy-body formation is an aggresome-related process: A hypothesis. Lancet Neurol. 3, 496–503.
125. Osterberg V. R., Spinelli K. J., Weston L. J., Luk K. C., Woltjer R. L. and Unni V. K. (2015) Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252–1260.
126. Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772–1775.
127. Pacheco C. R., Morales C. N., Ramírez A. E., Muñoz F. J., Gallegos S. S., Caviedes P. A., Aguayo L. G. and Opazo C. M. (2015) Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J. Neurochem. 132, 731–741.
128. Padovani A., Costanzi C., Gilberti N. and Borroni B. (2006) Parkinson's disease and dementia. Neurol. Sci. 27(Suppl 1), S40–S43.
129. Paleologou K. E., Kragh C. L., Mann D. M. A., Salem S. A., Al-Shami R., Allsop D., Hassan A. H., Jensen P. H. and El-Agnaf O. M. A. (2009) Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132, 1093–1101.
130. Paleologou K. E., Oueslati A., Shakked G. et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 3184–3198.
131. Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P. J., Pöyhönen M. and Paetau A. (2014) A novel a-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35, 2180.
132. Paslawski W., Mysling S., Thomsen K., Jørgensen T. J. D. and Otzen D. E. (2014) Co-existence of two different α-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass spectrometry. Angew. Chem. Int. Ed. Engl. 53, 7560–7563.
133. Pieri L., Madiona K., Bousset L. and Melki R. (2012) Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894–2905.
134. Plotegher N., Gratton E. and Bubacco L. (2014) Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim. Biophys. Acta 1840, 2014–2024.
135. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
136. Prots I., Veber V., Brey S., Campioni S., Buder K., Riek R., Böhm K. J. and Winner B. (2013) α-synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288, 21742–21754.
137. Proukakis C., Dudzik C. G., Brier T., MacKay D. S., Cooper J. M., Millhauser G. L., Houlden H. and Schapira A. H. (2013) A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80, 1062–1064.
138. Qin Z., Hu D., Han S., Hong D.-P. and Fink A. L. (2007) Role of different regions of alpha-synuclein in the assembly of fibrils. Biochemistry 46, 13322–13330.
139. van Raaij M. E., Segers-Nolten I. M. J. and Subramaniam V. (2006) Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys. J. 91, L96–L98.
140. van Raaij M. E., van Gestel J., Segers-Nolten I. M. J., de Leeuw S. W. and Subramaniam V. (2008) Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory. Biophys. J. 95, 4871–4878.
141. Radivojac P., Iakoucheva L. M., Oldfield C. J., Obradovic Z., Uversky V. N. and Dunker A. K. (2007) Intrinsic disorder and functional proteomics. Biophys. J. 92, 1439–1456.
142. Ramirez E. P. C. and Vonsattel J. P. G. (2014) Neuropathologic changes of multiple system atrophy and diffuse lewy body disease. Semin. Neurol. 34, 210–216.
143. Recasens A., Dehay B., Bové J. et al. (2014) Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362.
144. Roberts H. L. and Brown D. R. (2015) Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules 5, 282–305.
145. Roberts R. F., Wade-Martins R. and Alegre-Abarrategui J. (2015) Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 138, 1642–1657.
146. Rockenstein E., Nuber S., Overk C. R. et al. (2014) Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137, 1496–1513.
147. Ronzitti G., Bucci G., Emanuele M. et al. (2014) Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release. J. Neurosci. 34, 10603–10615.
148. van Rooijen B. D., Claessens M. M. and Subramaniam V. (2010) Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS ONE 5, e14292.
149. Rutherford N. J., Moore B. D., Golde T. E. and Giasson B. I. (2014) Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein. J. Neurochem. 131, 859–867.
150. Sahay S., Ghosh D., Dwivedi S., Anoop A., Mohite G. M., Kombrabail M., Krishnamoorthy G. and Maji S. K. (2015) Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein. J. Biol. Chem. 290, 7804–7822.
151. Sarafian T. A., Ryan C. M., Souda P., Masliah E., Kar U. K., Vinters H. V., Mathern G. W., Faull K. F., Whitelegge J. P. and Watson J. B. (2013) Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human alpha-synuclein. PLoS ONE 8, e63557.
152. Satake W., Nakabayashi Y., Mizuta I. et al. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303–1307.
153. Schell H., Hasegawa T., Neumann M. and Kahle P. J. (2009) Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 160, 796–804.
154. Schmidt F., Levin J., Kamp F., Kretzschmar H., Giese A. and Bötzel K. (2012) Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes. PLoS ONE 7, e42545.
155. Schoch S., Deák F., Königstorfer A., Mozhayeva M., Sara Y., Südhof T. C. and Kavalali E. T. (2001) SNARE function analyzed in synaptobrevin/VAMP knockout mice. Science 294, 1117–1122.
156. Scholz S. W., Houlden H., Schulte C. et al. (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65, 610–614.
157. Serpell L. C., Berriman J., Jakes R., Goedert M. and Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897–4902.
158. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583–595.
159. Shen J., Du T., Wang X., Duan C., Gao G., Zhang J., Lu L. and Yang H. (2014) α-Synuclein amino terminus regulates mitochondrial membrane permeability. Brain Res. 1591, 14–26.
160. Shibasaki Y., Baillie D. A., St Clair D. and Brookes A. J. (1995) High-resolution mapping of SNCA encoding alpha-synuclein, the non-A beta component of Alzheimer's disease amyloid precursor, to human chromosome 4q21.3–>q22 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 71, 54–55.
161. Siddiqui A., Chinta S. J., Mallajosyula J. K., Rajagopolan S., Hanson I., Rane A., Melov S. and Andersen J. K. (2012) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 53, 993–1003.
162. Simón-Sánchez J., Schulte C., Bras J. M. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308–1312.
163. Singleton A. B., Farrer M., Johnson J. et al. (2003) Alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
164. Smith W. W., Margolis R. L., Li X., Troncoso J. C., Lee M. K., Dawson V. L., Dawson T. M., Iwatsubo T. and Ross C. A. (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544–5552.
165. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A. and Wolozin B. (2003) Aggregated and monomeric α-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278, 11753–11759.
166. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
167. Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. and Goedert M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208.
168. Stefanis L., Larsen K. E., Rideout H. J., Sulzer D. and Greene L. A. (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549–9560.
169. Stöckl M., Claessens M. M. A. E. and Subramaniam V. (2012) Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers. Mol. BioSyst. 8, 338–345.
170. Südhof T. C. and Rizo J. (2011) Synaptic vesicle exocytosis. Cold Spring Harb. Perspect. Biol. 3, a005637.
171. Sweers K., van der Werf K., Bennink M. and Subramaniam V. (2011) Nanomechanical properties of α-synuclein amyloid fibrils: a comparative study by nanoindentation, harmonic force microscopy, and Peakforce QNM. Nanoscale Res. Lett. 6, 270.
172. Sweers K. K. M., Segers-Nolten I. M. J., Bennink M. L. and Subramaniam V. (2012a) Structural model for α-synuclein fibrils derived from high resolution imaging and nanomechanical studies using atomic force microscopy. Soft Matter 8, 7215–7222.
173. Sweers K. K. M., van der Werf K. O., Bennink M. L. and Subramaniam V. (2012b) Atomic force microscopy under controlled conditions reveals structure of c-terminal region of α-synuclein in amyloid fibrils. ACS Nano 6, 5952–5960.
174. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A., L Dawson V., Dawson T. M. and Ross C. A. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919–926.
175. Tanaka M., Kim Y. M., Lee G., Junn E., Iwatsubo T. and Mouradian M. M. (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625–4631.
176. Tanik S. A., Schultheiss C. E., Volpicelli-Daley L. A., Brunden K. R. and Lee V. M. Y. (2013) Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288, 15194–15210.
177. Tauro B. J., Greening D. W., Mathias R. A., Ji H., Mathivanan S., Scott A. M. and Simpson R. J. (2012) Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 56, 293–304.
178. Tenreiro S., Reimão-Pinto M. M., Antas P. et al. (2014) Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's Disease. PLoS Genet. 10, e1004302.
179. Thayanidhi N., Helm J. R., Nycz D. C., Bentley M., Liang Y. and Hay J. C. (2010) Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 21, 1850–1863.
180. Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. and Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy Bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405–44411.
181. Tosatto L., Andrighetti A. O., Plotegher N., Antonini V., Tessari I., Ricci L., Bubacco L. and Dalla Serra M. (2012) Alpha-synuclein pore forming activity upon membrane association. Biochim. Biophys. Acta 1818, 2876–2883.
182. Tsigelny I. F., Sharikov Y., Wrasidlo W., Gonzalez T., Desplats P. A., Crews L., Spencer B. and Masliah E. (2012) Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279, 1000–1013.
183. Tsigelny I. F., Sharikov Y., Kouznetsova V. L. et al. (2015) Molecular determinants of α-synuclein mutants’ oligomerization and membrane interactions. ACS Chem. Neurosci. 6, 403–416.
184. Urbanelli L., Magini A., Buratta S., Brozzi A., Sagini K., Polchi A., Tancini B. and Emiliani C. (2013) Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel) 4, 152–170.
185. Uversky V. N. (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 21, 211–234.
186. Valente E. M., Abou-Sleiman P. M., Caputo V. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.
187. Vamvaca K., Volles M. J. and Lansbury P. T. (2009) The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J. Mol. Biol. 389, 413–424.
188. Vargas K. J., Makani S., Davis T., Westphal C. H., Castillo P. E. and Chandra S. S. (2014) Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34, 9364–9376.
189. Vilar M., Chou H.-T., Lührs T., Maji S. K., Riek-Loher D., Verel R., Manning G., Stahlberg H. and Riek R. (2008) The fold of alpha-synuclein fibrils. Proc. Natl Acad. Sci. USA 105, 8637–8642.
190. Volles M. J. and Lansbury P. T. (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595–4602.
191. Wales P., Pinho R., Lázaro D. and Outeiro T. F. (2013) Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J. Parkinsons. Dis. 3, 415–459.
192. Wang L., Das U., Scott D. A., Tang Y., McLean P. J. and Roy S. (2014) α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 24, 2319–2326.
193. Waudby C. A., Camilloni C., Fitzpatrick A. W. P., Cabrita L. D., Dobson C. M., Vendruscolo M. and Christodoulou J. (2013) In-cell NMR characterization of the secondary structure populations of a disordered conformation of α-synuclein within E. coli cells. PLoS ONE 8, e72286.
194. Waxman E. A. and Giasson B. I. (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402–416.
195. Winner B., Jappelli R., Maji S. K. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194–4199.
196. Winslow A. R., Chen C. W., Corrochano S. et al. (2010) α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190, 1023–1037.
197. Withers G. S., George J. M., Banker G. A. and Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Dev. Brain Res. 99, 87–94.
198. Wood S., Wypych J., Steavenson S., Louis J., Citron M. and Biere A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509–19512.
199. Xie W. and Chung K. K. K. (2012) Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J. Neurochem. 122, 404–414.
200. Xilouri M., Vogiatzi T., Vekrellis K., Park D. and Stefanis L. (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515.
201. Xilouri M., Brekk O. R. and Stefanis L. (2013) Alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol. Neurobiol. 47, 537–551.
202. Xu S., Zhou M., Yu S., Cai Y., Zhang A., Uéda K. and Chan P. (2006) Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun. 342, 330–335.
203. Xue W. F., Hellewell A. L., Gosal W. S., Homans S. W., Hewitt E. W. and Radford S. E. (2009) Fibril fragmentation enhances amyloid cytotoxicity. J. Biol. Chem. 284, 34272–34282.
204. Yamin G., Uversky V. N. and Fink A. L. (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542, 147–152.
205. Zarranz J. J., Alegre J., Gómez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173.
206. Zhang L., Zhang C., Zhu Y., Cai Q., Chan P., Uéda K., Yu S. and Yang H. (2008) Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 1244, 40–52.
207. Zhou W., Long C., Reaney S. H., Monte D. A. Di., Fink A. L. and Uversky V. N. (2010) Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim. Biophys. Acta 1802, 322–330.